Insider at

04

Insider transactions

05
0 buys (P) 0 sells (S) Net: $0 + 1 non-open-market transaction below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

1 other filing hidden
DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
Dec. 19, 2019 DTIL P 2,235 $12.08 $26,999 2,485 Direct +894.00% Acquired -98.3% (price as of 2026-10-02)
Dec. 19, 2019 DTIL P 250 $12.09 $3,022 250 Direct · Acquired -98.3% (price as of 2026-10-02)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
June 8, 2020 DTIL Employee Stock Option (Right to Buy) Common Stock (133,206) $8.21 June 7, 2030 133,206 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 1 holding

07

Securities held when first becoming an insider, per SEC Form 3.

DateTickerSecuritySharesOwnership
Oct. 8, 2019 DTIL Employee Stock Option (Right to Buy)→ Common Stock (200,000) 200,000 Direct

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

DTIL

M.D. Chief Medical Officer
Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2020 $430,000 $146,200 · $726,001 · · $11,179 $1,313,380
2019 $286,667 $150,534 · $1,737,812 · · $6,832 $2,181,845

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.